Source: Reuters

Novartis has intensified its presence in digital technology after its recent mobile-phone based app launch, aimed to help collect data from people participating in eye disease studies. 

According to Reuters, it is using Apple’s ResearchKit for its “FocalView” application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. 

Chief Executive Vas Narasimhan is plowing resources into digital technology in a bid to boost trial success, save time and cut costs. Back in March, he revealed plans for up to 10 remote clinical trials by 2022 using U.S. partner Science 37’s mobile technology.

“Optimising digital technology in research and development, particularly in ophthalmic disease, could have a marked impact on the quality of the data we capture,” explained Bertrand Bodson, who as chief digital officer was elevated to Novartis’s executive committee this year. 

“We believe apps like FocalView…can help accelerate the development of treatments.”

Patients with eye problems may face mobility issues, and Novartis hope the app could reduce the hassle of collecting reliable data. 

More on these topics